BIOMAT Database Logo BIOMAT Database Logo

Carboplatin infusion in relapsed and refractory acute myeloid leukemia--a Southwest Oncology Group trial. 1995

J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
University of California, Davis, Division of Hematology and Oncology, UC Davis Cancer Center, Sacramento 95817, USA.

Carboplatin (CBDCA) is an active agent in the treatment of acute leukemia and is associated with limited extramedullary toxicity. Simultaneous phase II trials were conducted by the Southwest Oncology Group in adult patients with relapsed or refractory acute myeloid leukemia (AML). CBDCA was given as a continuous infusion at a dose of 300 mg/m2 daily for 5 days. Three (8%) of the 37 eligible patients in the relapsed group achieved complete remissions (CRs) lasting 3, 4, and 26 months. Entry of patients was stopped early in the refractory group due to slow accrual and in the relapsed group due to low CR rate. For both groups combined, the CR rate was 3/45 or 7% (95% confidence interval 3-18%). There were 12 fatal toxicities. Four patients died of intracerebral hemorrhage, three of infection, and five of hepatic and/or renal failure. Nonhematologic grade 4 toxicity included diarrhea in three patients, hyperbilirubinemia in four, and mucositis and renal toxicity in one each. These results suggest that CBDCA should not be considered for treatment of relapsed or refractory AML patients with prior high-dose therapy.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002543 Cerebral Hemorrhage Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA. Brain Hemorrhage, Cerebral,Cerebral Parenchymal Hemorrhage,Hemorrhage, Cerebral,Intracerebral Hemorrhage,Hemorrhage, Cerebrum,Brain Hemorrhages, Cerebral,Cerebral Brain Hemorrhage,Cerebral Brain Hemorrhages,Cerebral Hemorrhages,Cerebral Parenchymal Hemorrhages,Cerebrum Hemorrhage,Cerebrum Hemorrhages,Hemorrhage, Cerebral Brain,Hemorrhage, Cerebral Parenchymal,Hemorrhage, Intracerebral,Hemorrhages, Cerebral,Hemorrhages, Cerebral Brain,Hemorrhages, Cerebral Parenchymal,Hemorrhages, Cerebrum,Hemorrhages, Intracerebral,Intracerebral Hemorrhages,Parenchymal Hemorrhage, Cerebral,Parenchymal Hemorrhages, Cerebral
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
[Carboplatin treatment by continuous infusion in combination for relapsed and refractory acute myeloid leukemia].
December 1994, Gan to kagaku ryoho. Cancer & chemotherapy,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study.
September 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Relapsed/refractory acute myeloid leukemia: any progress?
November 2017, Current opinion in oncology,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Treatment for Relapsed/Refractory Acute Myeloid Leukemia.
June 2021, HemaSphere,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
March 2017, Current treatment options in oncology,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
December 2010, British journal of haematology,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Phase II clinical trial of carboplatin in relapsed and refractory leukemia.
October 1992, Leukemia,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Colchicine in refractory chronic lymphocytic leukemia. A Southwest Oncology Group study.
January 1983, Investigational new drugs,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
October 2000, Leukemia research,
J L Welborn, and K J Kopecky, and F J Meyers, and R Veith, and M Shurafa, and J H Doroshow, and S P Balcerzak, and F R Appelbaum
Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
August 1986, Cancer treatment reports,
Copied contents to your clipboard!